501332-69-0

501332-69-0 structure

Name: Idetrexed
Chemical Name: L-γ-Glutamyl-N-(4-{[(6S)-2-(hydroxymethyl)-4-oxo-4,6,7,8-tetrahyd ro-1H-cyclopenta[g]quinazolin-6-yl](2-propyn-1-yl)amino}benzoyl)- D-glutamic acid
CAS Number: 501332-69-0
Molecular Formula: C₃₂H₃₃N₅O₁₀
Molecular Weight: 647.63
Catalog: Signaling Pathways Apoptosis Thymidylate Synthase
Create Date: 2017-12-16 04:30:32
Modify Date: 2024-01-11 17:52:05
Idetrexed is a thymidylate synthase inhibitor specifically transported into alpha-folate receptor (alpha-FR)-overexpressing tumors. BGC 945 inhibited thymidylate synthase with a Ki of 1.2 nmol/L[1][2].

Name	L-γ-Glutamyl-N-(4-{[(6S)-2-(hydroxymethyl)-4-oxo-4,6,7,8-tetrahyd ro-1H-cyclopenta[g]quinazolin-6-yl](2-propyn-1-yl)amino}benzoyl)- D-glutamic acid

Description	Idetrexed is a thymidylate synthase inhibitor specifically transported into alpha-folate receptor (alpha-FR)-overexpressing tumors. BGC 945 inhibited thymidylate synthase with a Ki of 1.2 nmol/L[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Thymidylate Synthase Research Areas >> Others
References	[1]. Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res. 2005 Dec 15;65(24):11721-8. [2]. Tochowicz A, Dalziel S, Eidam O, O'Connell JD 3rd, Griner S, Finer-Moore JS, Stroud RM. Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells. J Med Chem. 2013 Jul 11;56(13):5446-55.